Back to results
US 2025/0152690 A1Published application
Novel live multi-antigenic recombinant vaccine against tuberculosis
AssigneeThe Regents of the University of California
InventorsMarcus A. Horwitz, Qingmei Jia
Life of this patent
Estimating the term…
Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a deadly global disease. Embodiments of the invention comprise an improved vaccine for generating an immune response and preventing or treating mycobacterial diseases such as tuberculosis in humans and animals. Embodiments of the invention also comprise a method for using the vaccine against such mycobacterial diseases.
Claims20
A composition of matter comprising at least one fusion protein having antigenic epitopes present in at least five Mycobacterium tuberculosis proteins selected from:
- immunogenic protein MPT64 (“23.5/Mpt64”), ESAT-6-like protein EsxH (“TB10.4/EsxH”), 6 kDa early secretory antigenic target (“ESAT6/EsxA”), ESAT-6-like protein EsxB (“CFP10/EsxB”), and diacylglycerol acyltransferase/mycolyltransferase Ag85B (“r30/Antigen 85B”);
- ESAT-6-like protein EsxN (“EsxN”);
- PPE family immunomodulator PPE68 (“PPE68”);
- ESX-1 secretion-associated protein EspA (“EspA”) and low molecular weight T-cell antigen TB8.4 (“TB8.4”), wherein the composition comprises live attenuated Listeria monocytogenes expressing the at least one fusion protein.
1 more element
Dependencies are inferred from the claim text.